Briana Kutscher, DPT Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 29650 Bradley Rd, Sun City, CA 92586 Phone: 951-672-0455 Fax: 951-672-0206 |
News Archive
VIVUS, Inc. today announced the issuance of three additional patents by the U.S. Patent and Trademark Office (USPTO) covering Qnexa, an investigational new drug candidate for the treatment of obesity. The three new patents are the second, third, and fourth patents to be granted in a series of patent applications VIVUS has filed that are directed to the Qnexa product and methods of using Qnexa in various therapeutic applications.
To their deep dismay, researchers at Mayo Clinic discovered several years ago that laboratory samples of anaplastic thyroid cancer (ATC) they were using to help them find new treatments for this lethal disease were probably some other kind of cancer. It quickly became evident that the situation in their lab was common throughout the world. Up to half of the cell lines that were supposed to originate from patients with this rare thyroid cancer were either colon or melanoma cancer.
Sudden Infant Death Syndrome SIDS, is still a threat to American babies finds the Centre for Disease Prevention and Control CDC in a new survey. The CDC states in its new Vital Signs report that despite the public campaigns and also the significant improvements in reducing the unsafe infant sleeping practices, there is still a threat to babies.
Merck today provided the following statement on the changes to the clinical studies for vorapaxar, one of the Company's investigational cardiovascular medicines, following an announcement from the two academic centers leading the studies of vorapaxar.
› Verified 8 days ago